This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Takeda GmbH
Takeda GmbH, a subsidiary of Takeda Pharmaceutical Company Limited, is a leading global biopharmaceutical firm headquartered in Germany. Established in 1781, Takeda has evolved into a powerhouse in the pharmaceutical industry, focusing on areas such as oncology, gastroenterology, and rare diseases. With a strong presence across Europe, Asia, and the Americas, the company is committed to advancing innovative therapies that address unmet medical needs. Takeda's core offerings include biologics, vaccines, and small molecules, distinguished by their commitment to patient-centric solutions and cutting-edge research. The company has achieved notable milestones, including significant advancements in immunology and oncology, solidifying its position as a trusted leader in the biopharmaceutical sector. With a rich history and a forward-thinking approach, Takeda GmbH continues to make impactful contributions to global health.
DitchCarbon Score
How does Takeda GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Takeda GmbH's score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
As of the latest available data, Takeda GmbH does not report specific carbon emissions figures. However, the company is part of a broader commitment to climate action through its parent organization, Takeda Pharmaceutical Company Limited. This relationship means that any climate initiatives or targets may be influenced by the overarching strategies set by the parent company. Takeda Pharmaceutical Company Limited has established various climate commitments, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These initiatives aim to align corporate emissions reductions with the latest climate science, although specific reduction targets for Takeda GmbH have not been detailed. The company is also involved in the RE100 initiative, which focuses on transitioning to 100% renewable electricity, and the Climate Pledge, although specific commitments at the subsidiary level remain unspecified. Overall, while Takeda GmbH does not provide direct emissions data or specific reduction targets, it is aligned with the climate strategies of its parent company, Takeda Pharmaceutical Company Limited, which is actively working towards significant sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Takeda GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
